Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIMO-2055
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- IMO-2055
- Accession Number
- DB06181
- Type
- Small Molecule
- Groups
- Investigational
- Description
- Not Available
- Synonyms
- Not Available
- External IDs
- EMD-1201081 / HYB-2055 / HYB2055 / IMO-2055
- International/Other Brands
- IMOxine
- Categories
- UNII
- 8566421Q5R
- CAS number
- 847484-35-9
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Pharmacology
- Indication
Investigated for use/treatment in renal cell carcinoma, solid tumors, and lung cancer.
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataDarbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with IMO-2055. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with IMO-2055. Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with IMO-2055. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with IMO-2055. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Not Available Lung Cancer Non-Small Cell Cancer (NSCLC) 1 1 Terminated Treatment Colorectal Cancers 1 1 Terminated Treatment Squamous Cell Carcinoma of the Head and Neck (SCCHN) 1 2 Completed Treatment Renal Cell Adenocarcinoma 1 2 Completed Treatment Squamous Cell Carcinoma of the Head and Neck Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Drug created on March 19, 2008 10:16 / Updated on December 02, 2019 07:19